CA3206481A1 - Compounds comprising a fibroblast activation protein ligand and use thereof - Google Patents

Compounds comprising a fibroblast activation protein ligand and use thereof

Info

Publication number
CA3206481A1
CA3206481A1 CA3206481A CA3206481A CA3206481A1 CA 3206481 A1 CA3206481 A1 CA 3206481A1 CA 3206481 A CA3206481 A CA 3206481A CA 3206481 A CA3206481 A CA 3206481A CA 3206481 A1 CA3206481 A1 CA 3206481A1
Authority
CA
Canada
Prior art keywords
cys
pro
group
phe
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3206481A
Other languages
English (en)
French (fr)
Inventor
Frank Osterkamp
Christian Haase
Eberhard Schneider
Jonas PROKSCH
Dirk Zboralski
Matthias Paschke
Christiane Smerling
Ulrich Reineke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3B Pharmaceuticals GmbH
Original Assignee
3B Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals GmbH filed Critical 3B Pharmaceuticals GmbH
Publication of CA3206481A1 publication Critical patent/CA3206481A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3206481A 2021-01-07 2022-01-07 Compounds comprising a fibroblast activation protein ligand and use thereof Pending CA3206481A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21150562.3A EP4050018A1 (en) 2021-01-07 2021-01-07 Compounds comprising a fibroblast activation protein ligand and use thereof
EPEP21150562 2021-01-07
PCT/EP2022/050294 WO2022148851A1 (en) 2021-01-07 2022-01-07 Compounds comprising a fibroblast activation protein ligand and use thereof

Publications (1)

Publication Number Publication Date
CA3206481A1 true CA3206481A1 (en) 2022-07-14

Family

ID=74215696

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3206481A Pending CA3206481A1 (en) 2021-01-07 2022-01-07 Compounds comprising a fibroblast activation protein ligand and use thereof

Country Status (9)

Country Link
US (1) US20240115745A1 (https=)
EP (2) EP4050018A1 (https=)
JP (1) JP2024503635A (https=)
KR (1) KR20230129260A (https=)
CN (1) CN116940586A (https=)
AU (1) AU2022205776A1 (https=)
CA (1) CA3206481A1 (https=)
IL (1) IL303926A (https=)
WO (1) WO2022148851A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3997103T3 (fi) 2019-07-08 2025-02-03 3B Pharmaceuticals Gmbh Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
US20250270238A1 (en) * 2022-05-20 2025-08-28 The Governors Of The University Of Alberta A new bifunctional linchpin that reacts selectively with cysteine residues to invoke cyclization while concurrently introducing a dotaga moiety for radiometal chelation
PE20251640A1 (es) * 2022-09-07 2025-06-24 3B Pharmaceuticals Gmbh Ligandos de antigeno de membrana especifica de la prostata (psma) y uso de los mismos
IL322552A (en) * 2023-02-10 2025-10-01 Chengdu New Radiomedicine Tech Co Ltd Polypeptide compound and its use
WO2024198838A1 (zh) * 2023-03-27 2024-10-03 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
KR20260026051A (ko) * 2023-06-14 2026-02-25 마리아나 온콜로지 인크. Dll3 표적화 펩티드 및 이의 구성체
CN121712788A (zh) * 2023-06-14 2026-03-20 马里亚纳肿瘤学公司 靶向dll3的肽及其构建体
CN121712787A (zh) * 2023-06-14 2026-03-20 马里亚纳肿瘤学公司 靶向dll3的肽及其构建体
WO2025082283A1 (zh) * 2023-10-16 2025-04-24 四川科伦博泰生物医药股份有限公司 环肽结构的配体化合物及其核素标记物、药物组合物及应用
GB202318958D0 (en) * 2023-12-12 2024-01-24 King S College London Compound
WO2025163556A1 (en) 2024-02-01 2025-08-07 Novartis Ag Methods for treating cancer
WO2025179168A1 (en) * 2024-02-22 2025-08-28 Mariana Oncology Inc. Synthesis of dll3-binding peptides
WO2026017046A1 (zh) * 2024-07-19 2026-01-22 晶核生物医药科技(南京)有限公司 一种环多肽、其制备方法和应用
WO2026021314A1 (zh) * 2024-07-22 2026-01-29 山东威智知科药业有限公司 Fap化合物及其用途
CN120590466A (zh) * 2025-08-06 2025-09-05 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) 一种靶向成纤维细胞活化蛋白的化合物及其应用
CN121045338A (zh) * 2025-11-05 2025-12-02 原子高科股份有限公司 一种靶向caix的环肽及其制备方法与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
ATE357509T1 (de) 1997-09-29 2007-04-15 Point Therapeutics Inc Stimulierung von hämatopoietischen zellen im vitro
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
EP1268550A2 (en) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
US7374898B2 (en) 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
US7399869B2 (en) 2005-05-19 2008-07-15 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
WO2008116054A1 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
WO2010036814A1 (en) 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
CA2776037A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd Anti-fibroblast activation protein antibodies and methods and uses thereof
CA2806021C (en) 2010-08-13 2019-05-21 Roche Glycart Ag Anti-fap antibodies and methods of use
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
CN109689115A (zh) 2016-06-10 2019-04-26 拜耳制药股份公司 放射性药物配合物
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EA202090776A1 (ru) 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
JP7801207B2 (ja) * 2019-07-08 2026-01-16 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
EP3763726A1 (en) * 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof

Also Published As

Publication number Publication date
WO2022148851A1 (en) 2022-07-14
CN116940586A (zh) 2023-10-24
AU2022205776A1 (en) 2023-07-27
EP4274836A1 (en) 2023-11-15
JP2024503635A (ja) 2024-01-26
EP4050018A1 (en) 2022-08-31
KR20230129260A (ko) 2023-09-07
IL303926A (en) 2023-08-01
US20240115745A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
US20240115745A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
US20230212549A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
JP7801207B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
AU2020310538B2 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
EP3763726A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
AU2022410422B2 (en) Carbonic anhydrase ix ligands
EP4610269A1 (en) Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use
TW202334177A (zh) 包含纖維母細胞活化蛋白配體之化合物和彼之用途
HK40121319A (en) Compounds comprising a fibroblast activation protein ligand and use thereof
HK40065560B (en) Compounds comprising a fibroblast activation protein ligand and use thereof
HK40065560A (en) Compounds comprising a fibroblast activation protein ligand and use thereof

Legal Events

Date Code Title Description
D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20240724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241213

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250214

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250320

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250320

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251111

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251111

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260106

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260106

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260219

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260219

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260219

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260219